ABSTRACT
AIM: The objectives were to determine trends in the use of chemotherapy as the initial treatment and to evaluate the comparative effectiveness of initial chemotherapy vs resection of the primary tumour on survival (intention-to-treat analysis) in Stage IV colorectal cancer (CRC). METHOD: This cohort study used 2000-2011 data from the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked database, including patients ≥ 66 years of age presenting with Stage IV CRC. Cox proportional hazards models and instrumental variable analysis were used to compare the effectiveness of chemotherapy as the initial treatment with resection of the primary tumour as the initial treatment, with 2-year survival as the end point. RESULTS: The use of chemotherapy as the first treatment increased over time, from 26.8% in 2001 to 46.9% in 2009 (P < 0.0001). The traditional Cox model showed that chemotherapy as the initial treatment was associated with a higher risk of mortality [hazard ratio (HR) = 1.35; 95% CI: 1.27-1.44]. When accounting for known and unknown confounders in an instrumental variable analysis, chemotherapy as the initial treatment suggested benefit on 2-year survival (HR = 0.68; 95% CI: 0.44-1.04); however, the association did not reach statistical significance. The study findings were similar in six subgroup analyses. CONCLUSION: The use of chemotherapy as the initial therapy for CRC increased substantially from 2001 to 2009. Instrumental variable analysis found that, compared with resection, chemotherapy as the initial treatment offers similar or better 2-year survival in patients with Stage IV CRC. Given the morbidity and mortality associated with colorectal resection in elderly patients, chemotherapy provides an option to patients who are not good candidates for resection.
Subject(s)
Antineoplastic Agents/therapeutic use , Colectomy/methods , Colorectal Neoplasms/therapy , Aged , Aged, 80 and over , Cohort Studies , Colorectal Neoplasms/mortality , Colorectal Neoplasms/pathology , Comparative Effectiveness Research , Female , Humans , Intention to Treat Analysis , Male , Neoplasm Staging , Proportional Hazards Models , SEER Program , Treatment OutcomeABSTRACT
A patient with pancreatic pseudocyst of the mediastinum is presented. Weight loss, chest or abdominal pain, and dyspnea are the most frequent symptoms of mediastinal pseudocyst. Chest roentgenogram frequently demonstrates a posterior mediastinal mass, and esophagogram always shows esophageal displacement. The diagnosis is confirmed by computerized axial tomography of the chest and abdomen. Cyst-gastrostomy is the operation of choice for this condition.
Subject(s)
Mediastinal Cyst/diagnostic imaging , Pancreatic Cyst/diagnostic imaging , Pancreatic Pseudocyst/diagnostic imaging , Aged , Humans , Male , RadiographyABSTRACT
The clinical experience with the activated clotting time (ACT) for the control of heparin and protamine therapy during cardiopulmonary bypass in 70 patients (50 adults and 20 children) is reviewed. After a standard dose of 2 mg/kg of body weight of heparin, the patient's ACT ranged from 210 to more than 600 seconds. The heparin dose required to accomplish an ACT of 500 seconds ranged from 1.3 to 4.7 mg/kg for adults and from 2 to 4.5 mg/kg for children. At the termination of bypass, the assessment of the patient's heparin level with the ACT allowed a more accurate reversal with protamine and markedly reduced the protamine requirements. Although the postoperative drainage was not significantly decreased, the total amount of blood transfusion and fresh-frozen plasma and platelet requirements were reduced by 30%, 20%, and 20% respectively. The simple, easy-to-use protocol is presented in detail.